))
Biomarkers, Pruritus Management, and Real-World Evidence in PBC
Manage episode 442330083 series 3603669
Content provided by Iridium Continuing Education. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Iridium Continuing Education or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
For CME Information & Credit Visit: https://www.iridiumce.com/leveling-up-pbc-podcast-2
Summary:
This conversation delves into the management of Primary Biliary Cholangitis (PBC), focusing on the role of biomarkers in treatment, the impact of pruritus on patients' quality of life, and the latest strategies for managing this condition. The discussion highlights the importance of effective monitoring and treatment options, as well as the need for new therapies to address the challenges faced by patients with PBC.
Takeaways:
- Biomarkers are crucial for monitoring PBC progression.
- Alkaline phosphatase and bilirubin are key indicators.
- UDCA is the first-line treatment for PBC.
- Pruritus affects up to 75% of PBC patients.
- Antihistamines are ineffective for PBC-related pruritus.
- Colestyramine is the first-line therapy for pruritus.
- New therapies for pruritus are in development.
- Patient quality of life is significantly impacted by pruritus.
- Real-world evidence shows under-treatment of pruritus.
- Effective management strategies are essential for patient adherence.
Sound Bites:
- "Biomarkers play a key role in the management of PBC."
- "Pruritus significantly impacts the lives of patients with PBC."
- "Antihistamines are not effective for PBC-related pruritus."
Clinical Resource Tool: https://www.iridiumce.com/leveling-up-pbc-management-resource
16 episodes
Share
